Antigenics Inc. was granted orphan drug designation by the FDA for its drug candidate, Oncophage (vitespen), which is used for the treatment of glioma (brain cancer). Currently, Oncophage is in a Phase 2 recurrent glioma study.

Oncophage is a patient-specific vaccine designed to reprogram the immune system to target only cancer cells bearing an ‘antigenic fingerprint’ derived from each individual’s tumor cells.  

For more information call (781) 674-4400 or visit www.antigenics.com.